AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Two clinical studies presented at the American Diabetes Association's (ADA) Scientific Sessions showed that ACTOS (pioglitazone HCl) has favorable effects on dyslipidemia and insulin resistance.
Dyslipidemia and insulin resistance are two key components of the metabolic syndrome, which is often exhibited in patients with type 2 diabetes.
"When you put the pieces together, these separate findings are very exciting because they show that ACTOS therapy can provide benefits extending beyond improvements in glucose levels," said Mehmood Khan, MD, FACE, senior vice president for medical and scientific affairs, Takeda…
Source: HighBeam Research, Studies show that ACTOS has positive effects on dyslipidemia, insulin...